Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Demonstrate the Efficacy and Safety of Desmopressin Orally Disintegrating Tablet for the Treatment of Nocturia in Adult Females

Next Previous
Search
Trial Profile

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Demonstrate the Efficacy and Safety of Desmopressin Orally Disintegrating Tablet for the Treatment of Nocturia in Adult Females

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Desmopressin (Primary)
  • Indications Nocturia
  • Focus Registrational; Therapeutic Use
  • Acronyms COMFORT
  • Sponsors Ferring Pharmaceuticals

Most Recent Events

  • 31 Aug 2018 Results of a responder analysis in subgroup of patients with nocturnal polyuria in two phase III trials (NCT01262456 and NCT01223937) presented at the 48th Annual Meeting of the International Continence Society
  • 31 Aug 2018 Results of a post-hoc analysis assessing efficacy and safety of desmopressin in subgroup of patients with nocturia and nocturnal polyuria in two phase III trials (NCT01262456 and NCT01223937) presented at the 48th Annual Meeting of the International Continence Society
  • 01 Nov 2016 According to Ferring Pharmaceuticals media release, based on the result of this trial, NOQDIRNA (oral lyophilisate desmopressin) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top